Adjusting for age, gender, WHO status, and number of metastases did not substantially change these results, and additional exclusion of patients with primary right-sided or BRAF-mutated cancer—all from the [89Zr]Zr-cetuximab visual positive group and with a very poor outcome—resulted in an OR for PD at 8 weeks of 1.01, and HRs for PFS and OS of 0.99 and 0.78 (all P values > 0.65; Tables S1–3). Here, BRAF is linked to cancer.